Markers of Severity (CD177,S100A8 &S100A12) in Sever Acute Respiratory Syndrome Coronavirus 2(SARS-COV-2) Patients

Not Applicable

• Conditions: COVID-19
• Interventions: Diagnostic Test: real time PCR

• Registration Number: NCT05201625
• Lead Sponsor: Sohag University

Brief Summary

Patients infected with covid-19 have a series of clinical manifestations, including fever, cough, myalgia or fatigue, dyspnea, even acute respiratory distress syndrome (ARDS), acute cardiac injury and secondary infection, and a lot of sever patients had to been admitted to the intensive care unit (ICU)

One of the hallmark of COVID 19 is the cytokine storm that provokes primarily pneumonia followed by systemic inflammation. besides the positive viral nucleic acid analysis and the representative pulmonary CT findings (bilateral distribution of patchy shadows and ground glass opacity), most individual patients showed the changes in several immunological and biological markers . CD177 which is one of the most clinically important neutrophil alloantigen because: i) it is a neutrophil-specific marker representative of neutrophil activation, ii) it was the most highly differentiated expressed gene in patients, and iii) the protein can be measured in the serum, making its use as a marker clinically applicable. It is expressed on neutrophils, neutrophilic metamyelocytes, and myelocytes . Given the contribution of the neutrophil activation pathway in the clustering of COVID-19 patients, neutrophil-activation features that could act as possible reliable markers of disease evolution.

Detailed Description

Not available

Study Timeline

• Study Start: 2021-12-15
• Status Verified: 2022-01
• Study First Submitted: 2022-01-03
• Study First Submitted QC: 2022-01-20
• Last Update Submitted: 2022-01-20
• Study First Posted: 2022-01-21
• Last Update Posted: 2022-01-21
• Primary Completion: 2022-12
• Study Completion: 2022-12

Recruitment & Eligibility

• Status: UNKNOWN
• Sex: All
• Target Recruitment: 90

Inclusion Criteria

• COVID 19 hospitalized patients (diagnosed by RT-PCR)

Exclusion Criteria

• Age below 18 years and above 80.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
ICU COVID 19 patients	real time PCR	ICU COVID 19 patients
control group	real time PCR	Healthy control group
non-ICU covid 19 patients	real time PCR	non-ICU covid 19 patients

Primary Outcome Measures

Name	Time	Method
Markers of severity(S100A8&S100A12) in Sever respiratory syndrome coronavirus 2 (SARS-COV-2) patients	one year	Measuring level of S100A8 and S100A12 by ELISA.
Markers of severity(CD177) in Sever respiratory syndrome coronavirus 2 (SARS-COV-2) patients	one year	- Measuring gene expression for CD 177 by RT-PCR and also by ELISA.; Measuring gene expression for CD 177 by RT-PCR and also by ELISA.

Trial Locations

Locations (1)

Sohag University Hospital; 🇪🇬 Sohag, Egypt